NORD's Seed Grants Fund Innovative Research for Rare Diseases

On October 1, 2026, the National Organization for Rare Disorders (NORD®) revealed the recipients of its latest round of seed grants. An impressive total of $145,000 has been awarded to support groundbreaking research targeting four rare conditions that often go underfunded and lack effective treatments. As a leader in the nonprofit sector, NORD serves over 30 million Americans grappling with rare diseases, and this funding initiative is a vital part of their commitment to advancing scientific inquiry and patient care.

The significant funding is a collaborative effort backed by various stakeholders, including the ACPMP Research Foundation and communities dedicated to pseudomyxoma peritonei, Peutz-Jeghers syndrome, and epidermodysplasia verruciformis, as well as Dylan’s Rare Chromosome Dream Team. This broad support highlights the urgent need for research in these spheres.

Awardees and Their Research Projects

The grant recipients include:

1. Dr. Antonio Sommariva from the Veneto Institute of Oncology in Padova, Italy, who has been awarded $50,000 to study appendix cancer, also known as pseudomyxoma peritonei (ACPMP). This form of cancer spreads from the appendix to the abdominal cavity, leading to severe complications. His project looks into TROP2, a promising therapeutic target that could redefine treatment approaches for affected patients.

2. Dr. Sanjay Ahuja, Chief Science Officer at Regal Intel in Warren, New Jersey, received a $25,000 grant to research epidermodysplasia verruciformis (EV), a rare skin condition linked to human papillomavirus (HPV) infection. His study aims to gather real-world evidence to improve screening and treatment protocols, enhancing the quality of life for those impacted.

3. A second grant of $40,000 also went to Dr. Ahuja for his work on Peutz-Jeghers syndrome (PJS). This hereditary condition poses a high risk of gastrointestinal complications and early cancers. His research seeks to correlate specific genetic mutations with patient health outcomes, paving the way for personalized care plans.

4. Dr. Giovanna Piovani from the University of Brescia, Italy, is set to receive $30,000 for her work on partial trisomy 6q, an extremely rare chromosomal disorder. Her investigation will combine clinical data with advanced genomic profiling to better understand this disorder and improve diagnostic and counseling processes for affected families.

The Importance of Early-Stage Funding

NORD's Rare Disease Research Grant Program mobilizes crucial funding for new, innovative research initiatives or clinical trials. This funding can often act as a springboard for more comprehensive support from larger agencies, such as the National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA). Since its inception in 1989, NORD has channeled over $9 million into research for rare diseases, which is particularly significant given that less than 5% of the approximately 10,000 known rare diseases have FDA-approved therapies.

Tracey Sikora, NORD's Vice President of Research and Clinical Programs, expressed enthusiasm for the recipients' projects, stating, "Their groundbreaking work represents a major leap forward for everyone affected by ACPMP, EV, PJS, and Partial Trisomy 6q. We're thrilled to champion innovative research that directly tackles the urgent, unmet needs of rare disease communities."

In conclusion, the funding granted by NORD will not only fuel critical research but also serves as a reminder of the ongoing challenges faced by those living with rare diseases. With such initiatives, there is hope for tangible advancements in understanding and treating these complex conditions. For more information on NORD’s efforts to advance research on rare diseases, visit rarediseases.org.